These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 31212989)

  • 1. Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors.
    Janning M; Kobus F; Babayan A; Wikman H; Velthaus JL; Bergmann S; Schatz S; Falk M; Berger LA; Böttcher LM; Päsler S; Gorges TM; O'Flaherty L; Hille C; Joosse SA; Simon R; Tiemann M; Bokemeyer C; Reck M; Riethdorf S; Pantel K; Loges S
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31212989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer.
    Sinoquet L; Jacot W; Gauthier L; Pouderoux S; Viala M; Cayrefourcq L; Quantin X; Alix-Panabières C
    Clin Chem; 2021 Nov; 67(11):1503-1512. PubMed ID: 34355741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.
    Ilié M; Szafer-Glusman E; Hofman V; Chamorey E; Lalvée S; Selva E; Leroy S; Marquette CH; Kowanetz M; Hedge P; Punnoose E; Hofman P
    Ann Oncol; 2018 Jan; 29(1):193-199. PubMed ID: 29361135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
    Guibert N; Delaunay M; Lusque A; Boubekeur N; Rouquette I; Clermont E; Mourlanette J; Gouin S; Dormoy I; Favre G; Mazieres J; Pradines A
    Lung Cancer; 2018 Jun; 120():108-112. PubMed ID: 29748004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer.
    Acheampong E; Abed A; Morici M; Spencer I; Beasley AB; Bowyer S; Asante DB; Lomma C; Lin W; Millward M; Gray ES
    Transl Lung Cancer Res; 2022 Mar; 11(3):440-451. PubMed ID: 35399573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of PD‑L1 expression and epithelial‑mesenchymal transition of circulating tumor cells in non‑small cell lung cancer.
    Jiang J; Mo W; Lian X; Cao D; Cheng H; Wang H
    Exp Ther Med; 2024 Jul; 28(1):294. PubMed ID: 38827467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer.
    Manjunath Y; Upparahalli SV; Avella DM; Deroche CB; Kimchi ET; Staveley-O'Carroll KF; Smith CJ; Li G; Kaifi JT
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31212653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC).
    Bergmann S; Coym A; Ott L; Soave A; Rink M; Janning M; Stoupiec M; Coith C; Peine S; von Amsberg G; Pantel K; Riethdorf S
    Oncoimmunology; 2020; 9(1):1738798. PubMed ID: 32391189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1.
    Schehr JL; Schultz ZD; Warrick JW; Guckenberger DJ; Pezzi HM; Sperger JM; Heninger E; Saeed A; Leal T; Mattox K; Traynor AM; Campbell TC; Berry SM; Beebe DJ; Lang JM
    PLoS One; 2016; 11(7):e0159397. PubMed ID: 27459545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer.
    Cheng Y; Wang T; Lv X; Li R; Yuan L; Shen J; Li Y; Yan T; Liu B; Wang L
    Cancer Manag Res; 2020; 12():2069-2078. PubMed ID: 32256114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.
    Anantharaman A; Friedlander T; Lu D; Krupa R; Premasekharan G; Hough J; Edwards M; Paz R; Lindquist K; Graf R; Jendrisak A; Louw J; Dugan L; Baird S; Wang Y; Dittamore R; Paris PL
    BMC Cancer; 2016 Sep; 16(1):744. PubMed ID: 27658492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer.
    Kallergi G; Vetsika EK; Aggouraki D; Lagoudaki E; Koutsopoulos A; Koinis F; Katsarlinos P; Trypaki M; Messaritakis I; Stournaras C; Georgoulias V; Kotsakis A
    Ther Adv Med Oncol; 2018; 10():1758834017750121. PubMed ID: 29383038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer.
    Dong J; Zhu D; Tang X; Lu D; Qiu X; Li B; Lin D; Li L; Liu J; Zhou Q
    PLoS One; 2019; 14(7):e0220306. PubMed ID: 31348821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System.
    Xu L; Mao X; Imrali A; Syed F; Mutsvangwa K; Berney D; Cathcart P; Hines J; Shamash J; Lu YJ
    PLoS One; 2015; 10(9):e0138032. PubMed ID: 26397728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of Circulating Tumor Cell Molecular Subtype in Pulmonary Vein Predicting Prognosis of Stage I-III Non-small Cell Lung Cancer Patients.
    Dong J; Zhu D; Tang X; Qiu X; Lu D; Li B; Lin D; Zhou Q
    Front Oncol; 2019; 9():1139. PubMed ID: 31737568
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy.
    Papadaki MA; Sotiriou AI; Vasilopoulou C; Filika M; Aggouraki D; Tsoulfas PG; Apostolopoulou CA; Rounis K; Mavroudis D; Agelaki S
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer.
    Koh Y; Yagi S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Higuchi M; Kanbara H; Nakanishi M; Ueda H; Yamamoto N
    Clin Lung Cancer; 2019 Jul; 20(4):270-277.e1. PubMed ID: 31005568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1
    Zhang L; Zhang X; Liu Y; Zhang T; Wang Z; Gu M; Li Y; Wang DD; Li W; Lin PP
    Cancer Lett; 2020 Jan; 469():355-366. PubMed ID: 31678168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?
    Acheampong E; Spencer I; Lin W; Ziman M; Millward M; Gray E
    Cancers (Basel); 2019 Jun; 11(7):. PubMed ID: 31262041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab.
    Nicolazzo C; Raimondi C; Mancini M; Caponnetto S; Gradilone A; Gandini O; Mastromartino M; Del Bene G; Prete A; Longo F; Cortesi E; Gazzaniga P
    Sci Rep; 2016 Aug; 6():31726. PubMed ID: 27553175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.